John-Joseph Borg

550 total citations
27 papers, 354 citations indexed

About

John-Joseph Borg is a scholar working on Economics and Econometrics, Physiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, John-Joseph Borg has authored 27 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Economics and Econometrics, 8 papers in Physiology and 7 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in John-Joseph Borg's work include Pharmaceutical Economics and Policy (13 papers), Pharmacovigilance and Adverse Drug Reactions (7 papers) and Biosimilars and Bioanalytical Methods (6 papers). John-Joseph Borg is often cited by papers focused on Pharmaceutical Economics and Policy (13 papers), Pharmacovigilance and Adverse Drug Reactions (7 papers) and Biosimilars and Bioanalytical Methods (6 papers). John-Joseph Borg collaborates with scholars based in Malta, Italy and Netherlands. John-Joseph Borg's co-authors include Robert Nisticò, M Pirozyński, Anthony Serracino‐Inglott, Daniela Melchiorri, František Dráfi, Sara Merlo, Tomas Salmonson, Dimitrios Kouvelas, Patricia Vella Bonanno and Luca Pani and has published in prestigious journals such as Nature Biotechnology, Nature Reviews Drug Discovery and Drug Discovery Today.

In The Last Decade

John-Joseph Borg

22 papers receiving 335 citations

Peers

Countries citing papers authored by John-Joseph Borg

Since Specialization

Citations

This map shows the geographic impact of John-Joseph Borg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John-Joseph Borg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John-Joseph Borg more than expected).

Fields of papers citing papers by John-Joseph Borg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John-Joseph Borg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John-Joseph Borg. The network helps show where John-Joseph Borg may publish in the future.

Co-authorship network of co-authors of John-Joseph Borg

This figure shows the co-authorship network connecting the top 25 collaborators of John-Joseph Borg. A scholar is included among the top collaborators of John-Joseph Borg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John-Joseph Borg. John-Joseph Borg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nivolumab Safety in Renal Cell Carcinoma: A Case Report 2023 ·Journal of Pharmacy Technology ·(unknown), (unknown), John-Joseph Borg, (unknown), (unknown), (unknown), Janet Sultana	0
2	An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on Masking Signal Detection in EudraVigilance 2023 ·Drug Safety ·(unknown), Jean‐Michel Dogné, Janet Sultana, Sabine M. J. M. Straus, Robert Nisticò, Anthony Serracino‐Inglott, John-Joseph Borg	9
3	Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy? 2023 ·Frontiers in Pharmacology ·Daniela Melchiorri, Sara Merlo, (unknown), John-Joseph Borg, František Dráfi	32
4	The changing landscape of treatment options in childhood acute lymphoblastic leukaemia 2022 ·Drug Discovery Today ·(unknown), Robert Nisticò, (unknown), Ole Weis Bjerrum, (unknown), (unknown), Anthony Serracino‐Inglott, John-Joseph Borg	4
5	Aducanumab for Alzheimer’s disease: A regulatory perspective 2021 ·Pharmacological Research ·Robert Nisticò, John-Joseph Borg	49
6	Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU 2021 ·Expert Opinion on Drug Safety ·(unknown), Katarina Vučić, Sabine M. J. M. Straus, (unknown), (unknown), Anthony Serracino‐Inglott, John-Joseph Borg	7
7	Improving the data quality of spontaneous ADR reports: a practical example from Malta 2021 ·Expert Opinion on Drug Safety ·(unknown), (unknown), (unknown), Anthony Serracino‐Inglott, John-Joseph Borg	3
8	A Healthy Gut for a Healthy Brain: Preclinical, Clinical and Regulatory Aspects 2020 ·Current Neuropharmacology ·Carla Petrella, Stefano Farioli‐Vecchioli, (unknown), Georgios Strimpakos, John-Joseph Borg, Mauro Ceccanti, Marco Fiore, Giovanni Monteleone, Robert Nisticò	18
9	Safety Implications of Low-Dose Amitriptyline in Neuropathic Pain 2019 ·OAR@UM (University of Malta) ·(unknown), (unknown), Anton Grech, (unknown), John-Joseph Borg, Anthony Serracino‐Inglott, Godfrey LaFerla	2
10	Regulatory sciences and translational pharmacogenetics: amitriptyline as a case in point 2019 ·Drug Metabolism and Personalized Therapy ·(unknown), (unknown), John-Joseph Borg, (unknown), Anthony Serracino‐Inglott, Godfrey LaFerla	0
11	Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency’s Committee for Medicinal Products for Human Use 2017 ·AAPS PharmSciTech ·(unknown), (unknown), Peter Richardson, Tomas Salmonson, Anthony Serracino‐Inglott, (unknown), John-Joseph Borg	12
12	Changing paradigms in bioequivalence trials submitted to the EMA for evaluation – A clinical and regulatory perspective 2016 ·Saudi Pharmaceutical Journal ·(unknown), (unknown), (unknown), Anthony Serracino‐Inglott, John-Joseph Borg	1
13	Multimodal management as requirement for the clinical use of anticachexia drugs - a regulatory and a clinical perspective 2015 ·Current Opinion in Supportive and Palliative Care ·John-Joseph Borg, Stefan D. Anker, Giuseppe Rosano, Anthony Serracino‐Inglott, Florian Strasser	8
14	Licensing of Generic Medicines, are there Any Challenges Left? A Pharmaceutical Regulatory Perspective 2014 ·Scientia Pharmaceutica ·John-Joseph Borg	0
15	Reflections on Decisions Taken on Well Established Use Medicinal Products by EU Regulators and the ECJ: A Pharmaceutical Regulatory Perspective 2014 ·Scientia Pharmaceutica ·John-Joseph Borg	5
16	Regulatory evaluation of Glybera in Europe — two committees, one mission 2013 ·Nature Reviews Drug Discovery ·Daniela Melchiorri, Luca Pani, Paolo Gasparini, Giulio Cossu, Jānis Ancāns, John-Joseph Borg, (unknown), Piotr Fiedor, Egbert Flory, I Hudson, Hubert G. M. Leufkens, Jan Müller‐Berghaus, Gopalan Narayanan, (unknown), Juris Pokrotnieks, (unknown), Tomas Salmonson, Christian K. Schneider	45
17	Medication errors through a national pharmacovigilance database approach: A study for Malta 2013 ·International Journal of Risk & Safety in Medicine ·(unknown), (unknown), Patricia Vella Bonanno, John-Joseph Borg	8
18	Reply to In support of the European Union biosimilar framework 2012 ·Nature Biotechnology ·(unknown), Christian K. Schneider, John-Joseph Borg, Falk Ehmann, Niklas Ekman, Esa Heinonen, (unknown), Marcel H. N. Hoefnagel, R. Martijn van der Plas, (unknown), (unknown), Robin Thorpe, (unknown), Asterios S. Tsiftsoglou, Camille Vleminckx, (unknown), (unknown), Martina Weise, (unknown)	4
19	Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to? 2011 ·Drug Safety ·John-Joseph Borg, (unknown), M Pirozyński, (unknown)	77
20	Where is Industry Getting it Wrong? A Review of Quality Concerns Raised at Day 120 by the Committee for Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products 2009 ·Journal of Pharmacy & Pharmaceutical Sciences ·John-Joseph Borg, Jean‐Louis Robert, George N. Wade, (unknown), M Pirozyński, Éric Abadie, Tomas Salmonson, Patricia Vella Bonanno	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact